# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

> **NCT02058160** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 736 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin glargine/lixisenatide (HOE901/AVE0010)
- **DRUG:** Insulin glargine (HOE901)
- **DRUG:** Metformin (Background Drug)

## Key facts

- **NCT ID:** NCT02058160
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 736 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058160, "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02058160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*